Bruker Corporation · NASDAQ:BRKR
Bruker — Investor Day (June 2021)
100 slides from Bruker's investor day presentation, Jun 17, 2021
Slide 1: Bruker Corporation 2021 Virtual Investor Day
INNOVATION WITH INTEGRITY Bruker Corporation (Nasdaq: BRKR) 2021 Virtual Investor Day June 17, 2021 Innovation with Integrity
Slide 2: Agenda
BRUKER CORP ORATI ON 2 0 2 1 IN VESTOR DAY Agenda 10:00 am to 1:00 pm EDT 01 Bruker Strategy & Opportunities Frank H. Laukien, President & CEO 05 Break Spatial Biology, Single-Cell Omics, and Cellular 02 Microbiology & Molecular Diagnostics Juergen Srega, President, Bruker CALID 06 Analysis Mark Mun
Slide 3: Safe Harbor Statement
BRUKER CORP ORATI ON Safe Harbor Statement Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 193
Slide 4: Bruker Strategy & Opportunities
INVESTOR DAY 2021 Bruker Strategy & Opportunities Breakout Opportunities in Proteomics & Spatial Biology Frank H. Laukien, Ph.D. Chairman, President & CEO June 17, 2021
Slide 5: Premier Provider of High-Performance Scientific Instruments and Life Science Solutions
IN VESTOR DAY 2 0 2 1 Premier Provider of High-Performance Scientific Instruments, and Life Science Research & Diagnostic Solutions Differentiated. Innovative. Entrepreneurial. ▪ Long track record of technological innovation ▪ Culture of disciplined entrepreneurialism ▪ Extensive collaborations with
Slide 6: Our Values of Innovation with Integrity drive Disciplined Entrepreneurialism
IN VESTOR DAY 2 0 2 1 Our Values of Innovation with Integrity drive Disciplined Entrepreneurialism Our Mission Our Values Our high-performance scientific instruments, life We value integrity, respect and trust within a science research and diagnostic solutions, and fast-paced and dynamic environment
Slide 7: Bruker Management Process - Unique Focus and Culture
IN VESTOR DAY 2 0 2 1 Bruker Management Process - Unique Focus and Culture Our unique Bruker Management Process has created a novel strategy, transformed our portfolio, accelerated growth and expanded margins within a culture of disciplined entrepreneurialism. Our diverse culture fosters With our fo
Slide 8: Why Invest in Bruker
IN VESTOR DAY 2 0 2 1 Why Invest in Bruker Project Accelerate 2.0 Operational Excellence ▪ Innovation & growth ▪ Commercial excellence ▪ Significant margin expansion ▪ Product R&D excellence ▪ Expanding margins ▪ Expanded large TAMs ▪ High ROIC philosophy ▪ At inflection point of expected ▪ Sustaina
Slide 9: Progress with Project Accelerate since June 2019 Investor Day
IN VESTOR DAY 2 0 2 1 Progress with Project Accelerate since June 2019 Investor Day ▪ Project Accelerate revenues now >50% of mix ▪ Significantly expanded scope of Accelerate initiatives - emerging breakout opportunities ▪ Project Accelerate ‘pulling up’ revenue growth and margins ▪ Operational Exce
Slide 10: Faster growth from six expanded high-growth, high-margin initiatives
P ROJECT ACCELERATE 2 .0 Faster growth from six expanded high-growth, high-margin initiatives Unbiased 4D-Proteomics & Unbiased Epiproteomics, Functional Consumables, Scientific Proteomics & Structural Biology, SCP Software & Aftermarket Multiomics Proteomics, PTMs, multiomic Consumables, assays, se
Slide 11: Project Accelerate 2.0: Expanded Strategic Scope and TAMs
IN VESTOR DAY 2 0 2 1 Project Accelerate 2.0: Expanded Strategic Scope and TAMs Unbiased Proteomics & Multiomics(1) Spatial Biology & Single-Cell Omics(2) Microbiology & Molecular Dx(3) Bruker SAM: Bruker SAM: Bruker SAM: $2B $1B $4B Overall TAM: Overall TAM: Overall TAM: $5-6B $3-5B >$20B (3) Micro
Slide 12: Project Accelerate 2.0
BRUKER 2021 AN D BEYON D Project Accelerate 2.0 • Focus on Technology Leadership & High Value Expanded Strategy & Larger TAMs: Scientific Instruments ▪ Unbiased Proteomics & Multiomics: $5-6B TAM • Enabling Life Science & Diagnostic Solutions ▪ Spatial Biology & Single-Cell Omics: $3-5B TAM • Emergi
Slide 13: Innovation with Integrity
Innovation with Integrity
Slide 14: Microbiology & Molecular Diagnostics
INVESTOR DAY 2021 Microbiology & Molecular Diagnostics Juergen Srega President, Bruker CALID Group June 17, 2021 Innovation with Integrity
Slide 15: Building A Rapidly Growing Business in a Large Addressable Market
M ICROBIOLOG Y & M OLECULAR DIAG N OSTICS Building A Rapidly Growing Business in a Large Addressable Market Clinical Diagnostics Microbiology & Molecular Dx (2020) Hygiene & Infection Control: $0.2B Bruker SAM: $4B Veterinary Medicine / Animal Health / Microbial Environmental Identification: $0.8B R
Slide 16: Bruker's Served Addressable Market Has Expanded Significantly
M ICROBIOLOG Y & M OLECULAR DIAG N OSTICS Bruker’s Served Addressable Market Has Expanded Significantly As Our Portfolio Has Grown Microbiology & Molecular Diagnostics SAM MALDI Biotyper® Microbial ID for the 21st Century ~$2B ~$4B SAM MBT STAR® Detection of Carbapenemase/ Cephalosporinase Activity(
Slide 17: MALDI Biotyper Installed Base Continues to Grow Rapidly
M ALDI ID IS THE N EW ‘G OLD -S T AN DA RD’ F OR F AST ID F ROM CULTURES MALDI Biotyper® Installed Base Continues to Grow Rapidly 2074 1020 1189 ▪ Better, faster, more cost-effective ID of bacteria and fungi ▪ Comprehensive species coverage 118 ▪ Near-universal microbial ID from cultures Market Expa
Slide 18: Rapid Recurring Revenue Growth with New Assays, Consumables, and Services
M ICROBIOLOG Y & M OLECULAR DIAG N OSTICS Rapid Recurring Revenue Growth with New Assays, Consumables, and Services, now also with PCR technology Microbiology & MDx Aftermarket revenue and mix: >$250 million >$130 million revenue revenue >$75 million revenue ▪ Revenue growth: organic 58% and with bo
Slide 19: MBT Sepsityper Kit US IVD: Democratizing Sepsis Diagnostics
M ICROBIOLOG Y & M OLECULAR DIAG N OSTICS MBT Sepsityper® Kit US IVD: Democratizing Sepsis Diagnostics ▪ Fast, near universal ID from positive blood cultures (PBCs) Direct ID from positive blood culture (PBC) Enabling change of therapy with earlier ID ▪ ID possible in ~20 minutes after PBC alert ▪ D
Slide 20: MBT Sepsityper Kit: Strong Customer Endorsement and Rapid US Uptake
M ICROBIOLOG Y & M OLECULAR DIAG N OSTICS FDA Clearance CE-IVD Marked MBT Sepsityper® Kit US IVD: Strong Customer Endorsement and Rapid US Uptake(1) “ …The MBT Sepsityper Kit US IVD will be the next step for a lot of clinical “ Rapid (MBT) Sepsityper identification has become instrumental in terms o
Slide 21: Trend Towards Rapid Antibiotic Resistance and Susceptibility Testing Further Expands SAM
M ICROBIOLOG Y & M OLECULAR DIAG N OSTICS Trend Towards Rapid Antibiotic Resistance and Susceptibility Testing Further Expands SAM On the Market In Development: work-in-progress MALDI Biotyper® MALDI Biotyper® Functional assays MBT-STAR Carba and MBT-STAR Development of targeted MBT FAST- Cepha give
Slide 22: Bruker-Hain: Differentiated PCR for Anchor Applications
M ICROBIOLOG Y & M OLECULAR DIAG N OSTICS Bruker-Hain: Differentiated PCR for Anchor Applications(1) ▪ Real-time PCR kits for differentiated anchor applications ▪ Market focus on Europe and Africa Tuberculosis/Mycobacteria Respiratory Disease Syndromic Panels Transplantation Diagnostics Expertise an
Slide 23: Bruker-Hain LiquidArray Technology Enables Cost Effective Mid-plex PCR Assays
M ICROBIOLOG Y & M OLECULAR DIAG N OSTICS Bruker-Hain LiquidArray® Technology Enables Cost Effective, Next Generation Mid-plex Real-Time PCR Assays Specialized PCR technique with LiquidArray® New Product Pipeline(1) affordable mid-plex capability FluoroType® STI Sexually transmitted Launched pathoge
Slide 24: New CE-IVD Quantitative Coronavirus Mid-Plex PCR Assay
DYN AMIC REAL -TIM E P CR ASSAY P ORTF OLIO EVOLUTION DURING THE COVID -19 P ANDEMIC New CE-IVD Quantitative Coronavirus Mid-Plex PCR Assay with Mutation Detection for Routine Variant Differentiation(1) ▪ FluoroType® SARS-CoV-2 varID Q is a CE-IVD labelled novel LiquidArray® mid-plex PCR panel ▪ Det
Slide 25: Changing Microbiology with Highly Differentiated Innovation
M ICROBIOLOG Y & M OLECULAR DIAG N OSTICS Changing Microbiology with Highly Differentiated Innovation AST Assays Bruker-Hain Diagnostics IR Biotyper MALDI Biotyper® Antibiotic Resistance/ Molecular Diagnostics/ Hospital Hygiene/ Microbial Identification Susceptibility Testing LiquidArray Panels Epid
Slide 26: Innovation with Integrity
Innovation with Integrity
Slide 27: GHz NMR Study of Protein Function
INVESTOR DAY 2021 GHz NMR Study of Protein Function Falko Busse, Ph. D. President, Bruker BioSpin Group June 17, 2021 Innovation with Integrity
Slide 28: NMR Video
IN VESTOR DAY 2 0 2 1 NMR Video © 2021 Bruker Innovation with Integrity | June 17, 2021 | 28
Slide 29: Innovation with Integrity
Innovation with Integrity
Slide 30: Unbiased, Deep 4D-Proteomics & Multiomics
INVESTOR DAY 2021 Unbiased, Deep 4D-Proteomics & Multiomics Single protein status Frank H. Laukien, Ph.D. Chairman, President & CEO June 17, 2021 Mechanistic or pathway protein panels
Slide 31: Proteomics is the measurement of proteins and their post-translational modifications
UN BIASED P ROTEOM ICS & M ULTIOM ICS Proteomics is the measurement of proteins and their post-translational modifications (PTMs, epiproteome) Decoding the proteome is essential to addressing disease and Untemplated improving the human condition ▪ Carbohydrates Alternative splicing, ▪ Lipids UTRs, i
Slide 32: Unique Bruker portfolio of tools for a large and rapidly expanding proteomics market
UN BIASED P ROTEOM ICS & M ULTIOM ICS Unique Bruker portfolio of tools for a large and rapidly expanding proteomics and protein research market Annualized Bruker revenue run rate: $200-$250M Bruker present SAM: $2B 4D-Proteomics by timsTOF Protein structure, function and binding by NMR Addressable T
Slide 33: timsTOF/PASEF: Unlocking unbiased, deep 4D-Proteomics and 4D-Epiproteomics
UN BIASED P ROTEOM ICS & M ULTIOM ICS timsTOF/PASEF: Unlocking the transformative power of unbiased, deep 4D-Proteomics and 4D-Epiproteomics Large-cohort plasma Pioneering 4D-Proteomics proteomics, PTMs for Large Cohort Validation Tissue & cell culture ▪ Excellent speed and robustness for 30-200 pro
Slide 34: timsTOF/PASEF: Significant Opportunities in Proteomics
UN BIASED P ROTEOM ICS & M ULTIOM ICS timsTOF/PASEF: Significant Opportunities in Proteomics, Even larger as Genomics Labs adopt Multiomics Biomarker Strategies >$1B SAM* >700 >7,000 Unbiased Unbiased Genomics Proteomics Labs (NGS) Labs >5,000 high resolution mass spectrometers ▪ timsTOF installed b
Slide 35: Introducing the timsTOF Pro 2
UN BIASED P ROTEOM ICS & M ULTIOM ICS Introducing the The standard for high throughput, high sensitivity, 4D-Proteomics improved 30 min “Since we started to work with the timsTOF Pro in February 2019, we have run more than 25,000 samples, of which about 5,000 have been non-depleted plasma digests. W
Slide 36: Introducing the timsTOF Pro 2: 4D-Epiproteomics
UN BIASED P ROTEOM ICS & M ULTIOM ICS Introducing the Unmatched CCS-aware 4D-Epiproteomics Performance “Besides its high sensitivity, a unique aspect of the timsTOF Pro instrument is its capability to resolve positional phosphorylation isomers in the gas phase, thus providing more detailed insight i
Slide 37: timsTOF Pro 2 performance
UN BIASED P ROTEOM ICS & M ULTIOM ICS ▪ 3x higher ion capacity, improved ion optics & electronics ▪ 3,500 protein, ~25k peptides in 30 min from 20 ng digest ▪ >6,000 proteins, >60k peptides in 60 min 200ng digest ▪ Improved methods for dia-PASEF and prm-PASEF ▪ Excellent for high-throughput plasma p
Slide 38: Unbiased, Deep and Quantitative Single Cell Proteomics
UN BIASED P ROTEOM ICS & M ULTIOM ICS Unbiased, Deep and Quantitative Single Cell Proteomics Bruker launches ultra-high sensitivity timsTOF SCP for unbiased, quantitative single-cell 4D-Proteomics, as a perfect complement to sc-RNA-seq 4.4x improvement in raw signal intensity. Signal from peptide (D
Slide 39: timsTOF SCP: revolutionize unbiased, quantitative single-cell biology
REV-O-LU- TI ON : A M OM EN TOUS CH AN GE IN A SITUATI ON timsTOF SCP: revolutionize unbiased, quantitative single-cell biology ▪ Ideal gene expression complement to scRNA-seq ▪ Launched on June 1st, 2021, 4 orders pre-launch ▪ 3,500 proteins, 25k peptides at 5ng loaded with EVOSEP Whisper ▪ Mann et
Slide 40: timsTOF flex: Spatially Resolved MALDI Imaging in Pathology Research
UN BIASED P ROTEOM ICS & M ULTIOM ICS timsTOF flex: Spatially Resolved MALDI Imaging in Pathology Research Unravelling the secrets of the tumor microenvironment with 4D-Multiomics “The patterns that we are seeing doing single cell profiles, based on our multi-disciplinary approaches really allows us
Slide 41: The TIMS/PASEF CCS-enabled 4D-Multiomics Revolution continues
UN BIASED P ROTEOM ICS & M ULTIOM ICS The TIMS/PASEF CCS-enabled 4D-Multiomics Revolution continues Xtreme sensitivity for single cell research SCP Single Cell MALDI SpatialOMx & ESI 4D-Lipidomics Multiomics 4D-Metabolomics 4D-Multiomics Tissue 4D-Proteomics Ultra-high sensitivity workhorse Plasma 4
Slide 42: Innovation with Integrity
Innovation with Integrity
Slide 43: Spatial Biology, Single-Cell Omics, and Cellular Analysis
2 0 2 1 INVESTOR DAY Spatial Biology, Single-Cell Omics, and Cellular Analysis Mark R. Munch, Ph. D. President, Bruker NANO Group
Slide 44: Spatial Biology, Single-Cell Omics, and Cellular Analysis: Why is this important?
BRUKER SP ATIAL BIOLOG Y Spatial Biology, Single-Cell Omics, and Cellular Analysis Why is this important? Information → increased mechanism insights Scientific evolution Bulk average Single cell, In situ spatial In situ spatial information ex situ information information, information, single-cell re
Slide 45: Our Spatial Portfolio
BRUKER SP ATIAL BIOLOG Y Our Spatial Portfolio Bulk/Ensemble Single-Cell Spatial Analysis Methods Methods Methods PROTEOMICS Canopy Biosciences TRANSCRIPTOMICS Vutara GENOMICS Acuity Spatial Genomics GRANULARITY OF Increased Insight INFORMATION Bulk average Single cell, ex situ In situ spatial, In s
Slide 46: Leveraging Our Fluorescence Imaging Expertise to Serve a Growing Segment
BRUKER SP ATIAL BIOLOG Y Leveraging Our Fluorescence Imaging Expertise to Serve a Significant Growing Segment Spatial Analysis Platforms Canopy Biosciences Vutara Bruker SAM Acuity ~$1B Spatial Genomics Overall TAM $3-5B In situ spatial, In situ spatial, single-cell sub-cellular resolution resolutio
Slide 47: Spatial & Single-Cell Targeted Proteomics: Canopy Biosciences
2 0 2 1 INVESTOR DAY Spatial & Single-Cell Targeted Proteomics Canopy Biosciences Spatial Biology – High-Plex Spatial Proteomics with True Single-Cell Resolution
Slide 48: Cell Suspensions Tissues
Cell Suspensions Tissues © 2021 Bruker Innovation with Integrity | June 17, 2021 | 48
Slide 49: Highly Quantitative Spatial High-Plex Proteomics Solutions: ChipCytometry
BRUKER SP ATIAL BIOLOG Y Highly Quantitative Spatial High-Plex Proteomics Solutions ChipCytometry Instruments Sample Chips and Carriers Analytical Software Standard, Certified Panels Custom Panels Project Analytical Services © 2021 Bruker Innovation with Integrity | June 17, 2021 | 49
Slide 50: Customers are after quantitative data/results
BRUKER SP ATIAL BIOLOG Y Customers are after quantitative data/results NKT cell CD8+ T-cell T-reg CD4+ T-cell Monocyte NK cell (CD45+, CD3+, CD56+) (CD45+, CD3+, CD8+, CD4-) (CD45+, CD3+, CD4+, FOXP3+) (CD45+, CD3+, CD4+, CD8-) (CD45+, CD14+, CD3-) (CD45+, CD3-, CD56+) CD56 CD45 CD3 CD8 CD45 CD3 CD4
Slide 51: Differentiated Performance for Differentiated Quantitative Results
BRUKER SP ATIAL BIOLOG Y Differentiated Performance for Differentiated Quantitative Results True Single-Cell Resolution High Dynamic Range Quantitative AI Algorithms True single-cell resolution achieved High dynamic range enables detection of low and high expression Autofluorescence High Expression
Slide 52: Differentiated Performance for Differentiated Quantitative Results
BRUKER SP ATIAL BIOLOG Y Differentiated Performance for Differentiated Quantitative Results True Single-Cell Resolution High Dynamic Range Quantitative AI Algorithms Absolute Cell Counts 9000 8513 For true 8000 Canopy quantitative 7000 5819 ChipCytometry 6000 5510 results: 5000 is unique in this 400
Slide 53: Applications and Flexibility to Customize to the Application
BRUKER SP ATIAL BIOLOG Y Applications and Flexibility to Customize to the Application melanoma Advantage in biomarker flexibility and customization study T-cell study • Over 214 validated biomarkers • Ability to use open-source markers and reagents… Wide range of antibody markers • Can customize mar
Slide 54: New Panels Launched
BRUKER SP ATIAL BIOLOG Y New Panels Launched IMMUNOLOGY IMMUNO-ONCOLOGY NEUROSCIENCE ▪ Immunology 15-plex PBMC ▪ Immuno-Oncology 20-plex ▪ Neuroscience 13-plex Tissue panel Tissue (FF) panel (FF, mouse) panel ▪ Covid-19 18-plex PBMC panel ▪ Immunology 16-plex Tissue (FFPE) panel © 2021 Bruker Innova
Slide 55: Human Breast Carcinoma – 20-plex
Human Breast Carcinoma – 20-plex BRUKER 2021 IN VESTOR DAY © 2021 Bruker Innovation with Integrity | June 17, 2021 | 55
Slide 56: Clear single-cell resolution, high dynamic range ... uniquely quantitative
Clear single-cell resolution, high dynamic range ... uniquely quantitative Cytotoxic T-cell Endothelial cell CD45 CD3 CD8 CD4 CD31 CD123 Pan-CK CD45 Macrophage Helper T-cell CD45 CD68 CD11c HLADR CD45 CD3 CD8 CD4 Regulatory T-cell Dendritic cell CD45 CD3 CD4 FOXP3 CD45 CD11c HLA-DR CD4 NK-cell NKT-c
Slide 57: Vutara VXL
2 0 2 1 INVESTOR DAY Vutara VXL Biology Workstation – Widefield and Super Resolution Platform for Spatial Omics with Wide Ranging Modalities Tubulin and Clathrin labeled with DNA-PAINT antibodies in BS-C-1 cells
Slide 58: Vutara VXL Biological Workstation for Spatial and Single-Cell Biology
BRUKER SP ATIAL BIOLOG Y Vutara™ VXL Biological Workstation for Spatial and Single-Cell Biology ▪ Versatile, powerful imaging workstation ▪ Integrated fluidics ▪ Integrated data analysis workflows ▪ Widefield and super-resolution (~20nm) imaging modes Actin (magenta), tubulin (yellow), tom20 (cyan),
Slide 59: Vutara VXL is a Versatile Platform for Spatial Omics Discovery
BRUKER SP ATIAL BIOLOG Y Vutara™ VXL is a Versatile Platform for Spatial Omics Discovery Multi-omics platform that OligoPaint / OligoSTORM DNA-PAINT supports several methods: ▪ OligoPaint ▪ smFISH ▪ OligoFISSEQ ▪ OligoSTORM ▪ Chromatin tracing (e.g., ORCA) TARGET TYPE OF MEASUREMENT ▪ DNA-PAINT Geno
Slide 60: Bruker's Differentiated Bi-plane Super-Resolution Technology
BRUKER SP ATIAL BIOLOG Y Bruker’s Differentiated Bi-plane Super-Resolution Technology Allows Increased Z-Resolution and Deeper Imaging for Tissues Bi-plane detection is exclusive to Bruker and offers: ▪ Increased z-resolution ▪ Optical stability ▪ Imaging of thicker samples Mouse Retinal Tissue (10μ
Slide 61: Acuity Spatial Genomics
2 0 2 1 INVESTOR DAY Acuity Spatial Genomics See the Entire 3D Genome in situ and at Single-cell and Sub-cellular Resolution
Slide 62: How does 1.8m of DNA pack into a ~5μm nucleus?
BRUKER SP ATIAL BIOLOG Y How does 1.8m of DNA pack into a ~5μm nucleus? Order of DNA in the Nucleus 1.8m of DNA in each human cell Contained in a ~5μm nucleus There is order to this structure © 2021 Bruker Innovation with Integrity | June 17, 2021 | 62
Slide 63: Genome organization is important….it is not just a linear sequence
BRUKER SP ATIAL BIOLOG Y Genome organization is important….it is not just a linear sequence In fact, it is highly organized… …and not static Chromosome Territories Loops / sub-TADs and Compartments Nuclear Positioning Nucleus Cell TADs (topologically associating domains) © 2021 Bruker Innovation wit
Slide 64: The programming starts in the 3D genome
BRUKER SP ATIAL BIOLOG Y The programming starts in the 3D genome RNA and Protein expression profiles are programmed from the genome FACTS OF THE 3D NUCLEOME 3D Genome mRNA Proteins Number of base pairs 3.2 billion Number of genes Genetic Transcript Protein approx. 20,000 blueprint code carriers expr
Slide 65: The programming starts in the 3D genome
BRUKER SP ATIAL BIOLOG Y The programming starts in the 3D genome RNA and Protein expression profiles are programmed from the genome FACTS OF THE 3D NUCLEOME What is the other 98% doing? Regions that regulate and modulate expression and replication • enhancer-promoter sequences Number of base pairs 3
Slide 66: Acuity Spatial Genomics Enables Direct Spatial Insights
BRUKER SP ATIAL BIOLOG Y Acuity Spatial Genomics Enables Direct Spatial Insights A New Frontier in 3D Genomic Analysis chromosome 3D conformation chromosomal compartments, sub-structures, TADs, and loops gene position on chromosome chromosome/gene copy number variations transcription complexes, enha
Slide 67: X Chromosome Example
BRUKER SP ATIAL BIOLOG Y X Chromosome Example Nuclear positioning of the chromosome Tracing genomic regions within the chromosome ▪ Understand the conformation and Chromosome X in the nucleus of folding of the chromosome a male fibroblast cell line ▪ Understand the spatial distribution of: ▪ Gene ta
Slide 68: Planned Suite of Solutions for Basic and Translational Research
BRUKER SP ATIAL BIOLOG Y Planned Suite of Solutions for Basic and Translational Research Designed to focus on the research and the data Kits and Reagents Integrated Imaging and Data Analysis Analytic Project Fluidics Platform Services © 2021 Bruker Innovation with Integrity | June 17, 2021 | 68
Slide 69: Acuity Spatial Genomics
BRUKER SP ATIAL BIOLOG Y Acuity Spatial Genomics In situ visualization of the 3D genome in single cells for translational research Linkages of genomic organization and chromosomal topology to disease and cell states © 2021 Bruker Innovation with Integrity | June 17, 2021 | 69
Slide 70: Quantitative Spatial Omics
BRUKER SP ATIAL BIOLOG Y Quantitative Spatial Omics © 2021 Bruker Innovation with Integrity | June 17, 2021 | 70
Slide 71: Innovation with Integrity
Innovation with Integrity
Slide 72: 2021 Guidance, Operational Excellence & Medium Term Financial Outlook
INVESTOR DAY 2021 2021 Guidance, Operational Excellence & Medium Term Financial Outlook Gerald Herman Executive Vice President & Chief Financial Officer June 17, 2021 Innovation with Integrity
Slide 73: Updated FY 2021 Guidance
IN VESTOR DAY 2 0 2 1 Updated FY 2021 Guidance (as of June 17, 2021) FY 2021 Updated Assumptions FY 2021 Year-over-Year (comparisons to May 5th , 2021 Guidance guidance in parentheses) ▪ Organic revenue growth: +13% to +15% ▪ FX revenue tailwind: approximately +3% Revenue Growth +16% to +18% (vs. +1
Slide 74: Bruker Financial Overview
IN VESTOR DAY 2 0 2 1 Bruker Financial Overview 2021 GUIDANCE METRICS $2.3B 18.5% $1.87 REVENUE(1) NON-GAAP OPERATING MARGIN (1) NON-GAAP EPS (1) 2020 BSI SEGMENTS END MARKET MIX (2) 2020 BRUKER GEOGRAPHIC MIX Academic & Government Research 44% 2020 BRUKER ROIC (3) Industrial Research & Other 26% 38
Slide 75: Historical Transformation Phase and Project Accelerate & Operational Excellence
IN VESTOR DAY 2 0 2 1 Historical Transformation Phase: 2014-2016 Project Accelerate & Operational Excellence: 2017 and beyond ORGANIC REVENUE GROWTH NON-GAAP OPERATING MARGIN NON-GAAP EPS MORE ACCELERATION 2017-2019 UP 740 BPS THAN DOUBLED $1.57 $2.1B 17.6% $1.9B 16.8% $1.40 $1.8B $1.8B 15.9% 15.0%
Slide 76: Medium Term Outlook – Key Drivers of Revenue Growth
BRUKER 2021 IN VESTOR DAY Medium Term Outlook – Key Drivers of Revenue Growth $2.85B(1) Other Project Bruker Core Microbiology & Accelerate 2.0 Spatial Biology & Operational Excellence for Proteomics & Molecular Dx Single-Cell Omics Initiatives growth, share & margins: Multiomics ▪ Unbiased, deep 4D
Slide 77: Medium Term Outlook – Key Drivers of Revenue Growth
IN VESTOR DAY 2 0 2 1 Medium Term Outlook – Key Drivers of Revenue Growth Other Project Breakout Core Accelerate 2.0 Opportunities 2021-G Revenue $1.0B $1.0B $0.3B 2.3B(1) Aftermarket Proteomics Bruker Total FY 2021-G Core Bruker Spatial Biology Revenue Semi Metrology Biopharma & Applied Microbiolog
Slide 78: Our Other Strategic Pillar - Operational Excellence
IN VESTOR DAY 2 0 2 1 Our Other Strategic Pillar - Operational Excellence ▪ Excellence in Operations, Commercial and Product R&D ▪ Driving growth, expanding gross and operating margins ▪ Proven and sustainable progress as foundation for further success Bruker Penang Facility Operational Efficiency C
Slide 79: Free Cash Flow - Improving Performance
IN VESTOR DAY 2 0 2 1 Free Cash Flow - Improving Performance FREE CASH FLOW $235 $191 $140 $111 $94 2016 2017 2018 2019 2020 SUMMARY ▪ Improved Free Cash Flow due to stronger profitability and working capital management ▪ Continuing focus on improving working capital ▪ CAPEX expected at 3 - 4% of re
Slide 80: R&D Investment - Leading Innovation
IN VESTOR DAY 2 0 2 1 R&D Investment - Leading Innovation BRUKER R&D AS % OF REVENUE 10% 10% Significant R&D investment in Project Accelerate 2.0 initiatives 9% ▪ Drives product innovation and profitable revenue growth ▪ Focus on breakout opportunities in proteomics & spatial biology 2019 2021-E 202
Slide 81: Medium Term Outlook
IN VESTOR DAY 2 0 2 1 Medium Term Outlook Towards $3B in Revenue and $3.00 Non-GAAP EPS by the Middle of the Decade REVENUE GROWTH NON-GAAP OPERATING MARGIN NON-GAAP EPS GROWTH EXPANSION $2.60–$3.00 $2.7B–$3.0B 20.7%–21.5% 17.6% 18.5% $2.3B 16.0% $2.1B $2.0B $1.87 $1.57 $1.35 2019 2020 2021-G 2024-O
Slide 82: Capital Deployment Strategy
IN VESTOR DAY 2 0 2 1 Capital Deployment Strategy Invest Sustain Return in Profitable Growth Financial Flexibility, Low Risk Capital to Shareholders ▪ Above peer R&D investment ▪ Strong, flexible balance sheet ▪ Annual dividend of $0.16 per ▪ S&M investments in Project ▪ Conservative debt levels sha
Slide 83: Appendix
INVESTOR DAY 2021 Appendix 83
Slide 84: Medium-Term Outlook – Financial Assumptions
IN VESTOR DAY 2 0 2 1 Medium-Term Outlook – Financial Assumptions R&D Investment as a % of Revenue 10% per year Non-GAAP Effective Tax Rate Decreases from ~30% in 2021 guidance to ~29% in 2022-2024 outlook Interest / Other Expense ~0.7% of revenue per year M&A Incremental M&A not included Dividend C
Slide 85: Acronyms
IN VESTOR DAY 2 0 2 1 Acronyms AFM Atomic Force Microscopy LSD Low single digits Bps Basis points MBT Maldi BioTyper CAGR Compound annual growth rate MS Mass Spectrometry CBRNE Chemical, Biological, Radiological, Nuclear and MSD Mid-single digits Explosives (detection) Nano-IR Nanoscale-infrared CE-
Slide 86: Reconciliation of GAAP Reported Revenue Growth to Organic Revenue Growth
IN VESTOR DAY 2 0 2 1 Reconciliation of GAAP Reported Revenue Growth to Organic Revenue Growth [$ m] 2014 2015 2016 2017 2018 2019 2020 GAAP revenue as of prior comparable period $1,839.4 $1,808.9 $1,623.8 $1,611.3 $1,765.9 $1,895.6 $2,072.6 Non-GAAP adjustments: Acquisitions and divestitures 2.9 (3
Slide 87: Reconciliation of Non-GAAP Operating Income, Profit Before Tax, Net Income, and EPS
IN VESTOR DAY 2 0 2 1 Reconciliation of Non-GAAP Operating Income, Non-GAAP Profit Before Tax, Non-GAAP Net Income, and Non-GAAP EPS [$ m, except per share amounts] 2014 2015 2016 2017 2018 2019 2020 GAAP operating income* $106.0 $160.2 $181.8 $219.5 $262.4 $300.9 $248.3 Non-GAAP adjustments: Restru
Slide 88: Reconciliation of GAAP and Non-GAAP Interest & Other Income (Expense), net
IN VESTOR DAY 2 0 2 1 Reconciliation of GAAP and Non-GAAP Interest & Other Income (Expense), net [$ m] 2014 2015 2016 2017 2018 2019 2020 GAAP Interest & Other Income (Expense), net* $(4.7) $(32.2) $(4.2) $(21.7) $(17.7) $(20.5) $(22.5) Non-GAAP Adjustments: - - - Sale of Product Line (8.3) 0.2 - -
Slide 89: Reconciliation of GAAP and Non-GAAP Earnings Per Share (Diluted)
IN VESTOR DAY 2 0 2 1 Reconciliation of GAAP and Non-GAAP Earnings Per Share (Diluted) 2014 2015 2016 2017 2018 2019 2020 GAAP Earnings Per Share (Diluted) $0.33 $0.60 $0.95 $0.49 $1.14 $1.26 $1.02 Non-GAAP adjustments: Restructuring costs 0.21 0.17 0.13 0.10 0.06 0.01 0.10 Acquisition-related costs
Slide 90: Reconciliation of GAAP Operating Cash Flow and Non-GAAP Free Cash Flow
IN VESTOR DAY 2 0 2 1 Reconciliation of GAAP Operating Cash Flow and Non- GAAP Free Cash Flow [$ m] 2016 2017 2018 2019 2020 GAAP operating cash flow $130.8 $154.4 $239.7 $213.4 $333.2 Non-GAAP Adjustments: Purchases of property, plant and equipment (37.1) (43.7) (49.2) (73.0) (98.2) Non-GAAP Free C
Slide 91: Reconciliation of Non-GAAP Return on Invested Capital (ROIC)
IN VESTOR DAY 2 0 2 1 Reconciliation of Non-GAAP Return on Invested Capital (ROIC) [$ m] 2016 2017 2018 2019 2020 Non-GAAP operating income* $242.5 $280.9 $317.9 $364.0 $317.2 Less: Non-GAAP Income Tax Provision (35.9) (64.7) (78.5) (96.6) (82.9) Non-GAAP operating income after tax $206.6 $216.2 $23
Slide 92: Non-GAAP Financial Measures
IN VESTOR DAY 2 0 2 1 Non-GAAP Financial Measures Additional information regarding our use of non-GAAP financial measures, including how we define and calculate such non-GAAP financial measures, is included on pages 43 to 44 under Part II, Item 7— Management’s Discussion and Analysis of Financial Co
Slide 93: ;
;
Slide 94: Presenter Bios
INVESTOR DAY 2021 Presenter Bios Innovation with Integrity
Slide 95: Frank H. Laukien, Ph.D. Chairman, President and CEO
EXECUTIVE BIO Frank H. Laukien, Ph.D. Chairman, President and CEO, Bruker Corporation ▪ Chairman, President and CEO of Bruker, and Bruker’s largest stockholder ▪ Leading Project Accelerate & Operational Excellence, and unique Bruker culture ▪ Brings perspective of significant stakeholder with in-dep
Slide 96: Juergen Srega President, Bruker CALID Group
EXECUTIVE BIO Juergen Srega President, Bruker CALID Group ▪ Over 30 years of experience managing global businesses of multinational corporations with strong leadership and broad technical and financial skills. ▪ Strong track record of building high-growth organizations that foster organizational, op
Slide 97: Falko Busse, Ph.D. President, Bruker BioSpin Group
EXECUTIVE BIO Falko Busse, Ph. D. President, Bruker BioSpin Group ▪ President, Bruker BioSpin Group, with responsibility for the Group’s global operations. ▪ 20 years of experience in management of significant growth opportunities at Philips Healthcare and its subsidiaries. ▪ Strong record in buildi
Slide 98: Mark R. Munch, Ph.D. President, Bruker NANO Group
EXECUTIVE BIO Mark R. Munch, Ph.D. President, Bruker NANOGroup and Corporate Executive Vice President ▪ President, Bruker Nano Group, with responsibility for the Group’s global operations. ▪ Executive Vice President of Bruker Corporation, focus on Bruker Management Processes and Global IT/ERP oversi
Slide 99: Gerald Herman Executive Vice President and Chief Financial Officer
EXECUTIVE BIO Gerald Herman Executive Vice President and Chief Financial Officer ▪ Chief Financial Officer since June 2018, after being named Interim Chief Financial Officer in March 2018. ▪ Joined Bruker in 2016 as Vice President and Corporate Controller. ▪ Track record of senior executive position
Slide 100: ;
;